Skip to main content
Eligibility
for people ages 18 years to 55 years
Location
at Berkeley, California and other locations
Dates
study started
Principal Investigator

Description

Summary

The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.

Details

The trial is an open label extension study. Eligible patients from the RPC01-201, RPC01-301, and RPC01-1001 trials diagnosed with relapsing Multiple Sclerosis (RMS) will be enrolled to receive study drug until the end of the trial or until the Sponsor discontinues the development program.

Keywords

Multiple Sclerosis MS RMS Relapsing Multiple Sclerosis

Eligibility

For people ages 18 years to 55 years

Eligibility Criteria:

  • Completed one of the parent trials: RPC01-201, RPC01-301 or RPC01-1001
  • Does not have a condition that would require withdrawal from one of the parent trials(RPC01-201, RPC01-301, RPC01-1001)
  • Has no conditions requiring treatment with a prohibited medication
  • Ability to provide written informed consent and to be compliant with the schedule of protocol assessments
  • Patients of reproduction potential (males and females) must practice an acceptable method of birth control

Locations

  • Receptos Site 110
    Berkeley, California, 94705, USA
  • Receptos Site 112
    Sacramento, California, 95817, USA
  • Receptos Study Site 120
    San Francisco, California, 94158, USA
  • Receptos Study Site 103
    Fresno, California, 93710, USA
  • Receptos Study Site 122
    Long Beach, California, 90806, USA

Details

Status
accepting new patients by invitation only
Start Date
Sponsor
Celgene
ID
NCT02576717
Phase
Phase 3
Lead Scientist
Bruce Cree
Study Type
Interventional
Last Updated
December 2016